Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
Nadler
J P
JP
Department of Medicine, State University of New York Health Science Center, Brookdale Hospital, Brooklyn.
Berger
J
J
Nord
J A
JA
Cofsky
R
R
Saxena
M
M
D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D065093:beta-Lactamase Inhibitors
D000995:Antitubercular Agents; D002969:Clavulanic Acids; D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000658:Amoxicillin